Literature DB >> 22759943

Selective aggregation of self-disorders in first-treatment DSM-IV schizophrenia spectrum disorders.

Elisabeth Haug1, Lars Lien, Andrea Raballo, Unni Bratlien, Merete Oie, Ole A Andreassen, Ingrid Melle, Paul Møller.   

Abstract

Converging evidence indicates that self-disorders (SDs) selectively aggregate in schizophrenia spectrum conditions. The aim of this study was to test the discriminatory power of SDs with respect to schizophrenia and nonschizophrenia spectrum psychosis at first treatment contact. SDs were assessed in 91 patients referred for first treatment through the Examination of Anomalous Self-experience (EASE) instrument. Diagnoses, symptoms severity, and function were assessed using the Structural Clinical Interview for the DSM-IV, Structured Clinical Interview for the Positive and Negative Syndrome Scale, Calgary Depression Scale for Schizophrenia, Young Mania Rating Scale, and Global Assessment of Functioning-Split Version. Most patients found it highly relevant to talk about SDs. EASE total score critically discriminated between schizophrenia, bipolar psychosis, and other psychoses. The EASE total score was the only clinical measure that showed a significant and robust association with the diagnosis of schizophrenia. Systematic exploration of anomalous self-experiences could improve differential diagnosis in first-treatment patients.

Entities:  

Mesh:

Year:  2012        PMID: 22759943     DOI: 10.1097/NMD.0b013e31825bfd6f

Source DB:  PubMed          Journal:  J Nerv Ment Dis        ISSN: 0022-3018            Impact factor:   2.254


  31 in total

1.  The core Gestalt of schizophrenia.

Authors:  Josef Parnas
Journal:  World Psychiatry       Date:  2012-06       Impact factor: 49.548

Review 2.  Schizophrenia, Subjectivity, and Mindreading.

Authors:  Matthew M Nour; Alvaro Barrera
Journal:  Schizophr Bull       Date:  2015-04-05       Impact factor: 9.306

3.  Self-Disorders and Clinical High Risk for Psychosis: An Empirical Study in Help-Seeking Youth Attending Community Mental Health Facilities.

Authors:  Andrea Raballo; Elena Pappagallo; Alice Dell' Erba; Nella Lo Cascio; Martina Patane'; Eva Gebhardt; Tommaso Boldrini; Laura Terzariol; Massimiliano Angelone; Alberto Trisolini; Paolo Girardi; Paolo Fiori Nastro
Journal:  Schizophr Bull       Date:  2016-01-12       Impact factor: 9.306

4.  Disturbance of minimal self (ipseity) in schizophrenia: clarification and current status.

Authors:  Barnaby Nelson; Josef Parnas; Louis A Sass
Journal:  Schizophr Bull       Date:  2014-03-11       Impact factor: 9.306

5.  Disturbances of the Basic Self and Prodromal Symptoms Among Young Adolescents From the Community: A Pilot Population-Based Study.

Authors:  Danny Koren; Liza Lacoua; Lily Rothschild-Yakar; Josef Parnas
Journal:  Schizophr Bull       Date:  2016-03-18       Impact factor: 9.306

Review 6.  Predictive Processing, Source Monitoring, and Psychosis.

Authors:  Juliet D Griffin; Paul C Fletcher
Journal:  Annu Rev Clin Psychol       Date:  2017-03-30       Impact factor: 18.561

Review 7.  Neurobiological Models of Self-Disorders in Early Schizophrenia.

Authors:  A Mishara; I Bonoldi; P Allen; G Rutigliano; J Perez; P Fusar-Poli; P McGuire
Journal:  Schizophr Bull       Date:  2015-09-18       Impact factor: 9.306

8.  Decreased Self-Concept Clarity in People with Schizophrenia.

Authors:  David Colin Cicero; Elizabeth A Martin; Theresa M Becker; John G Kerns
Journal:  J Nerv Ment Dis       Date:  2016-02       Impact factor: 2.254

9.  Schizophrenia and the sense of self.

Authors:  Aubrey M Moe; Nancy M Docherty
Journal:  Schizophr Bull       Date:  2013-08-22       Impact factor: 9.306

Review 10.  Disordered Selfhood in Schizophrenia and the Examination of Anomalous Self-Experience: Accumulated Evidence and Experience.

Authors:  Julie Nordgaard; Mads Gram Henriksen; Lennart Jansson; Peter Handest; Paul Møller; Andreas Rosen Rasmussen; Karl Erik Sandsten; Lars Siersbæk Nilsson; Maja Zandersen; Dan Zahavi; Josef Parnas
Journal:  Psychopathology       Date:  2021-08-12       Impact factor: 1.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.